SQ-LIP-000022 · v1.5 (archived) · View current version →

What clinical criteria and stage/type classification systems are used to diagnose and grade lipedema, and how reliable are they?

Knowledge freshness = share of the 26 indexed evidence sources from the last 5 years (newest 2026, oldest 2012) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

consistent   conflicting   refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.

Answer over time

Each node is a published version of the answer — open one to read the answer exactly as it stood then.

Consistent claims

• SCR-LIP-000190 consistent
  In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using three clinical variables—bruising, body disproportion, and non-swollen feet (cuffing sign)—classified patients with 100% accuracy; lipedema was characterized by symmetry (100%), spared feet (93.5%), pain (92%), bruising (90.6%), telangiectasias (89.9%), and family history (84.7%), and staged 1-4 (stage I 37.7%, II 34.8%, III 22.5%, IV 5.1%).
  Building evidence for diagnosis of lipedema: using a classification and regression tree (CART) algorithm to differentiate lipedema from lymphedema patients — FORNER-CORDERO et al. (2025)
• SCR-LIP-000361 consistent
  The first Dutch lipedema guidelines define clinical diagnostic criteria requiring all five Wold anamnestic criteria (disproportionate fat distribution, poor fat response to weight loss, pain/easy bruising, touch sensitivity/extremity fatigue, no pain reduction with elevation) plus at least one regional physical-examination criterion pair, with extra criteria (bimanual palpation pain, distal-knee lipomas) compensating when up to two criteria are absent, while noting the absence of objective diagnostic criteria.
  First Dutch guidelines on lipedema using the international classification of functioning, disability and health — Halk & Damstra (2017)
• SCR-LIP-000364 consistent
  In a cross-sectional survey of 969 Spanish lipedema patients, diagnoses used the Schingale type I-IV classification (type III 41.7%, type IV 36.8%, type II 17.8%, type I 3.7%) and a modified Wolf/Herbst 13-criteria symptom scale; the authors validated a threshold of ≥6 of 13 symptoms (Mann-Whitney p=0.666 showing no distributional difference between diagnosed and undiagnosed groups), and diagnosis often required multiple consultations (51.2% needed ≥3 specialists).
  The Advanced Care Study: Current Status of Lipedema in Spain, A Descriptive Cross-Sectional Study — Carballeira Braña & Poveda Castillo (2023)
• SCR-LIP-000369 consistent
  In an observational study of 360 Italian women with lipedema, structured clinical evaluation applied a 3-stage staging system and anatomical type classification (1-5), with stage distribution of 39.7% stage 1, 40.0% stage 2, and 20.3% stage 3, and anatomical type 3 most prevalent (89.7%), while clinical signs including pinch pain (99.4%), subcutaneous nodules (98.9%), and progressive pain scores by stage (p<0.001) were documented.
  Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History — Patton et al. (2024)
• SCR-LIP-000371 consistent
  This review describes lipedema clinical presentation using a classification of 5 types by anatomical fat distribution (I: hip/buttocks; II: hip to knee; III: hip to ankle; IV: also arms in ~80% of women; V: calf only) and 4 stages (I: smooth skin with enlarged hypodermis; II: palpable nodules with peau d'orange; III: deforming fat masses with folds; IV: lipolymphedema with positive Stemmer sign), and notes that only 46.2% of surveyed vascular consultants could recognize the disease.
  Lipedema: A Call to Action! — Buso et al. (2019)
• SCR-LIP-000372 consistent
  In a cross-sectional study of 115 Saudi patients with lower-limb edema, clinical diagnosis of lipedema used a structured assessment including signs (cuff/collar sign, Stemmer sign, telangiectasias, non-pitting orthostatic edema), severity grading 1-4 and anatomical type classification 1-5; clinical criteria confirmed lipedema in 71% (82/115), grade 2 was most common (31%), type 3 (hip-to-ankle) predominant (47%), and the cuff/collar sign correlated with advanced stages (80% of those with the sign were ≥grade 2).
  Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024)
• SCR-LIP-000373 consistent
  The German S1 guideline defines lipedema diagnostic criteria (onset at puberty/pregnancy/menopause, disproportional adipose proliferation sparing hands and feet, periarticular cuffing, palpation hypersensitivity, increasing edema, negative Stemmer sign) and classifies it by three morphological stages and by anatomical location, with differential criteria distinguishing it from lipohypertrophy, obesity, and lymphedema.
  S1 guidelines: Lipedema — Reich‐Schupke et al. (2017)

Conflicting claims

• None indexed yet.

Refining / contextual

• SCR-LIP-000199 refines
  In a DXA body composition study, the leg fat mass/total fat mass index distinguished lipedema patients from healthy controls with AUC=0.90 (sensitivity 0.95, specificity 0.73 at cutoff 0.383) across all BMI strata, with elevated leg fat proportion (0.451 vs 0.354) and inverted trunk/legs ratio (0.960 vs 1.502), while appendicular lean mass and total bone density did not differ.
  Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema — Buso et al. (2022)
• SCR-LIP-000188 refines
  A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328).
  Criação de questionário e modelo de rastreamento de lipedema — Amato et al. (2020)
• SCR-LIP-000189 context
  In a prospective cohort of 83 women diagnosed with lipedema using clinical criteria, lipedema was classified by clinical stage (most often stage 1, 39.8%) and type (most often type III, hips to ankles, 74.7%), and lymphoscintigraphic abnormality grade showed no significant association with clinical stage (p=0.142), type (p=0.505), Stemmer's sign (p=0.506), age, or BMI.
  Hallazgos linfogammagráficos en pacientes con lipedema — Forner-Cordero et al. (2018)
• SCR-LIP-000191 refines
  Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging.
  Lipedema and Dercum's Disease: A New Application of Bioimpedance — Crescenzi et al. (2019)
• SCR-LIP-000192 refines
  This systematic review of molecular and cellular lipedema studies argues that the current staging system based on Wold (1951) is insufficient for the disease's clinical heterogeneity and proposes its revision to incorporate comorbidities (obesity, lymphedema), pre-surgical weight, and family history.
  Lipedema Research—Quo Vadis? — Ernst et al. (2023)
• SCR-LIP-000193 refines
  The S2k lipedema guideline defines lipedema as painful, disproportionate, symmetrical adipose distribution occurring almost exclusively in women, and states that diagnosis is clinical, requiring disproportion plus concomitant symptoms (pain), while morphological staging should NOT be used as a measure of severity, the 'nodular' criterion should not be used for diagnosis, and no instrument (duplex, ultrasound, MRI, lymphoscintigraphy, laboratory tests) can confirm lipedema (they serve only for differential diagnosis).
  S2k guideline lipedema — Faerber et al. (2024)
• SCR-LIP-000194 context
  This systematic review describes lipedema diagnosis as primarily clinical and outlines a 3-stage clinical staging system (Stage I normal skin with small palpable nodules; Stage II irregular surface with liposclerosis; Stage III lobular deformation with peau d'orange) plus Schingale's 5-type classification (I hips/thighs, II to knees, III to ankles, IV arms+legs, V lipo-lymphedema), with key differential signs (negative Stemmer, foot dorsum sparing) and noncontrast CT reported at 95% sensitivity and 100% specificity.
  Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review — Forner‐Cordero et al. (2012)
• SCR-LIP-000195 refines
  A review of 13 tools used to quantify lipedema limbs (8 imaging, 5 clinical measurement) found highly heterogeneous and poorly documented protocols — e.g., tape measurement used inconsistent anatomical sites and volume formulas, and ultrasound studies omitted machine settings — with clinimetric reliability reported in only a minority of studies, limiting reproducibility and cross-study comparison.
  Assessment Tools to Quantify the Physical Aspects of Lipedema: A Systematic Review — Eason et al. (2025)
• SCR-LIP-000358 refines
  The authors propose a clinical-ultrasonographic diagnostic algorithm for abdominal lipedema using maximum criteria (symmetric abdominal fat deposition + ultrasonographic evidence + inelastic skin), major criteria (pain on palpation + non-response to diet/exercise), and minor criteria (easy bruising + heaviness), correlating abdominal involvement with lipedema stage (31% in stage II, 70% in stage III).
  Abdominal Lipedema: Clinical Diagnosis and Management Through a Proposed Diagnostic Algorithm — Bruno & Cilluffo (2025)
• SCR-LIP-000359 refines
  This systematic review of 61 articles found that lipedema diagnosis relies largely on clinical features from observational cohorts, case series, and expert consensus with few randomized trials, and concluded that standardized diagnostic criteria and validated patient-reported outcomes are still lacking.
  Lipedema Diagnosis, Clinical Manifestations, and Therapeutics: A Systematic Review — Vazirnia et al. (2026)
• SCR-LIP-000360 refines
  This study proposes adding two intermediate stages (1.5 and 2.5) to the classical 3-stage lipedema system and objectively characterizes progression using standardized item-by-item physical exam (modified Wold criteria), Beighton hypermobility score, infrared thermography, and bioimpedance spectroscopy, finding that BMI increases linearly with stage (r2=0.5628, p<0.0001), peripheral hypothermia and total body water rise with stage, L-Dex lymphedema risk is significantly elevated only at stage 3, and pain is present in 70% at stage 1 (not obligatory early).
  New Characterization of Lipedema Stages: Focus on Pain, Water, Fat and Skeletal Muscle — Al-Ghadban et al. (2025)
• SCR-LIP-000362 context
  This narrative review describes the lipedema clinical classification into types I-V and stages I-IV, lists differential diagnoses (lymphedema, phlebedema, lipohypertrophy, Dercum's disease, Launois-Bensaude lipomatosis), and reports proposed imaging cut-offs (e.g., high-resolution ultrasound subcutaneous thickness 11.7 mm pretibial, DXA leg-fat/total-fat ratio 0.383), while identifying the absence of an objective, easy-to-perform diagnostic imaging test as a critical gap.
  Lipedema: What we don’t know — van la Parra et al. (2023)
• SCR-LIP-000363 refines
  In a systematic review of 32 studies (1154 patients), imaging methods proposed for characterizing lipedema include ultrasound (increased subcutaneous adipose tissue), lymphoscintigraphy (slowed lymphatic flow, inter-limb asymmetry), CT (symmetrical bilateral soft tissue enlargement without skin thickening or edema), MRI, MR lymphangiography (enlarged lymphatic vessels up to 2 mm), and DXA (leg fat mass/BMI ≥0.46 or leg fat/total fat ≥0.384), but their overall diagnostic performance was limited.
  Diagnostic imaging in lipedema: A systematic review — van la Parra et al. (2024)
• SCR-LIP-000365 context
  This narrative review describes lipedema as a clinical entity diagnosed by clinical presentation and differentiated from obesity and lymphedema, but notes it remains poorly characterized with frequent misdiagnosis and a lack of high-quality studies precisely defining its features.
  Lipedema: Clinical Features, Diagnosis, and Management — Mortada et al. (2025)
• SCR-LIP-000366 context
  In a Swiss cohort of 381 lipedema patients classified by type (I-V) and stage (1-4), advanced stage correlated with age and BMI, but a Stemmer sign was positive in only 4.0% and validated questionnaire scores (HADS, BPI, FSS, SF-36) did not differ significantly between stages (p>0.5), revealing a dissociation between morphological stage and symptom burden.
  Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025)
• SCR-LIP-000367 context
  This selective review states that lipedema diagnosis is exclusively clinical with no specific biomarker available, complementary exams used only to exclude differential diagnoses, and notes that diagnosis remains challenging due to heterogeneous presentation and the absence of objective characterization instruments; in Germany liposuction was approved for stage III patients.
  Lipedema—Pathogenesis, Diagnosis, and Treatment Options — Kruppa et al. (2020)
• SCR-LIP-000368 context
  In a Spanish cohort of 1,803 lipedema patients, 46.6% were classified as Schingale stage IV or V, and the authors propose a novel clinical examination approach (including signs such as bilateral trochanteritis and ligamentous hyperlaxity) to support rapid diagnosis.
  Clinical Signs at Diagnosis and Comorbidities in a Large Cohort of Patients with Lipedema in Spain — Simarro Blasco et al. (2025)
• SCR-LIP-000370 refines
  A retrospective study of 34 women with lipedema using high-frequency B-mode ultrasound (10-15 MHz) across three platforms proposes a new qualitative Lipedema Dermal and Hypodermal Classification (LDHC) with four stages distinguishing preserved architecture (LDHC 1), bulging architecture (LDHC 2), inflammatory phenotype with hyperechoic nodules (LDHC 3), and fibrotic 'marbled' phenotype with septal verticalization (LDHC 4), intended to complement existing anatomical and functional classifications.
  The Challenge of a Qualitative Ultrasonographic Classification in Lipedema — Vargas et al. (2025)
• SCR-LIP-000374 context
  Using ICG lymphography in 45 women with lipedema classified by different types and stages, lymphatic function (dye transit speed) correlated with symptom duration (T25' vs duration r=-0.469, p=0.037) rather than with lipedema stage or fat accumulation, and a linear lymphatic pattern was found in 100% of patients with no major anatomical abnormalities.
  Indocyanine green lymphography as novel tool to assess lymphatics in patients with lipedema — Buso et al. (2021)

Major uncertainty

No diagnostic 'gold standard' exists: lipedema diagnosis rests on expert-consensus clinical criteria with no confirmatory instrument, and formal inter-rater/test-retest reliability of the clinical criteria and of the morphological stage and anatomical type classifications is almost entirely untested—reliability was reported in only 2 of 13 measurement tools, staging dissociates from symptom and objective burden, and a large survey could not distinguish diagnosed from undiagnosed patients on a standardized symptom scale. Whether proposed objective adjuncts (DXA index, pretibial ultrasound, bioimpedance) or newer proposals (intermediate stages, LDHC, abdominal criteria) improve reproducibility remains unvalidated, and the evidence base is dominated by single-center observational studies with unknown risk of bias.

Version history

• SQ-LIP-000022 · v1.5 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000022 · v1.4 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000022 · v1.3 — 2026-05-31 — This update added 16 sources that broadened the documented guideline/consensus base (Dutch and German S1 guidelines), corroborated the type/stage systems and their cohort distributions, and—most importantly—strengthened the evidence that morphological stage is dissociated from symptom burden and objective measures (notably the Swiss 381-patient cohort and ICG lymphography data), while introducing several still-unvalidated refinement proposals (intermediate stages 1.5/2.5, ultrasound LDHC, abdominal-lipedema criteria) and two systematic reviews reaffirming the absence of standardized, validated criteria. · view this version
• SQ-LIP-000022 · v1.2 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000022 · v1.1 — 2026-05-31 — This update built the answer from scratch, establishing that lipedema diagnosis is clinically based with recognized criteria and stage/type systems, and registering converging moderate-grade evidence that clinical criteria discriminate well (AUC 0.86–0.91; CART 100%) while morphological staging is unreliable as a severity measure and objective adjunct tools remain inadequately validated. · view this version
• SQ-LIP-000022 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000003). · snapshot not archived

Key references

DOI:10.1159/000527138 · DOI:10.1590/1677-5449.200114 · DOI:10.1016/j.remn.2018.06.008 · DOI:10.23736/s0392-9590.25.05207-1 · DOI:10.1089/lrb.2019.0011 · DOI:10.3390/jpm13010098 · DOI:10.1111/ddg.15513 · DOI:10.1111/j.1758-8111.2012.00045.x · DOI:10.1089/lrb.2024.0102 · DOI:10.1007/s00266-025-05192-1 · DOI:10.1111/ijd.70227 · DOI:10.3390/life15091397 · DOI:10.1177/0268355516639421 · DOI:10.1016/j.bjps.2023.05.056 · DOI:10.1111/obr.13648 · DOI:10.3390/ijerph20176647 · DOI:10.1055/a-2530-5875 · DOI:10.1371/journal.pone.0319099 · DOI:10.3238/arztebl.2020.0396 · DOI:10.20944/preprints202510.1397.v1 · DOI:10.3390/ijms25031599 · DOI:10.4236/jbise.2025.184008 · DOI:10.1002/oby.22597 · DOI:10.1097/gox.0000000000006173 · DOI:10.1111/ddg.13036 · DOI:10.1016/j.mvr.2021.104298

← All questions